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a b s t r a c t 
Background: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coro- 
navirus. Although general and local public health report deathly cases, case fatality rates are still largely 
unknown. Thus, we sought to evaluate the mortality of COVID-19. 
Methods: We searched PubMed and EMBASE databases for articles evaluating the clinical characteristics 
of COVID-19 patients that included clinical outcomes, between December 2020 and 24 April 2020. Two 
authors performed an independent selection using predefined terms of search. 
Results: We retrieved 33 studies with a total of 13,398 patients with COVID-19 diagnosis. The mortality 
rate of the COVID-19 patients was 17.1% (95% CI 12.7; 22.7, I 2 = 96.9%). For general patients admitted to 
the hospital (excluding critical care-only studies) the mortality rate of the COVID-19 was 11.5% (95% CI 
7.7; 16.9, I 2 = 96.7%). Among critical illness studies ( n = 7) we found a 40.5% mortality (95% CI 31.2; 
50.6, I 2 = 91.8%). 
Conclusion: High COVID-19 mortality among general admitted patients and critical care cases should 
guide resources allocations and economic burden calculations during the pandemics. 





























The first reported case of COVID-19 in Wuhan, China, at the end 
f 2019, determined the zero point of a timeline that will still go 
n for several months, not to say years. A fast and widespread out- 
reak throughout China soon expanded its borders to other coun- 
ries. 
According to the report of the World Health Organization 
WHO) as of 7 April 2020, COVID-19 has affected 1,279,722 pa- 
ients over 212 countries/territories and has caused 72,614 deaths, 
f which only 6.5% of cases and 4.6% of deaths have been in 
hina [ 1 ]. Both the incidence and mortality of COVID-19 vary sig- 
ificantly among different countries/territories and estimation of 
OVID-19 outcomes during the pandemics is imprecise and, at a Conflicts of interest: No conflicts of interest. 
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047-2797/© 2021 Elsevier Inc. All rights reserved. ertain point, misleading [ 2 , 3 ]. According to China’s data, case fa- 
ality rate is estimated around 7% in hospitalized patients [4] and 
.3% overall [5] . The numbers resulting from case fatality rate cal- 
ulations are reached by dividing the number of known deaths by 
he number of confirmed cases. However, this equation will only 
e adequate at the end of the outbreak, as the duration of the dis- 
ase is variable and, especially in the most severe cases admitted 
o hospitals, may extend several months beyond the initial clinical 
resentation. 
At the present time, several isolated case series reports have 
een published with preliminary conclusions on risk factors for the 
OVID-19 related death. Age has soon become one of the main 
isk factors for death from COVID-19, giving way to all protec- 
ive measures that all countries are implementing to protect this 
opulation from viral transmission, both in the ascending and de- 
cending limbs of the local epidemic curves [6] . Deathly outcomes 
ere eventually related to respiratory failure in the vast majority 
f the patients [7] . In line with this fact, the common early find-
ngs on chest CT scans of COVID-19 hospitalized patients are multi- 









































































































obar and bilateral lesions, patchy ground glass opacities [ 8 , 9 ] that
rogress to a reticular pattern and will continue a linear evolution 
o consolidation on unfavorable outcome cases [10] . 
Apparently, COVID-19 patients with underlying cardiovascular 
iseases (CVD) have a proven significant increased risk of death, 
ith mortality reaching 10.5% [11] in general Chinese populations. 
oreover, the sub-population of hospitalized patients with under- 
ying CVD and escalation of T- troponin levels have shown the 
ighest reported fatality rates [12] . The exact pathophysiological 
echanism underlying myocardial injury caused by COVID-19 is 
ot fully understood, but there is growing evidence that COVID- 
9 patients with previous CVD are more susceptible to a fatal out- 
ome. 
The scarcity of detailed data on COVID-19 clinical and outcome 
haracteristics, considering its newness, as well as the universal 
ommon effort s from the scientific community to daily reporting 
n new data on the infection, justify the need for a specific meta- 
nalysis on this particular topic. 
aterial and methods 
atabase search and study selection 
Two reviewers (CF and AM) systematically and independently 
earched for clinical studies by using combinations of the follow- 
ng search terms: “covid,” “fatality,” “death,” “mortality,” and “out- 
ome.” The US National Library of Medicine (PubMed) and Ex- 
erpta Medical Database (EMBASE) were included in the search, 
hich initially took place in the first week of April 2020 and then 
as updated with additional information on April 23rd 2020. First, 
tudies that were retrieved were screened according to their titles 
nd abstracts. Only studies on humans were included. Second, the 
ull text of the selected articles was evaluated to make a final de- 
ermination for inclusion. Finally, the reference lists of the eligible 
rticles were checked for potentially relevant articles (not included 
n the first online searches). The full texts of these additional ar- 
icles were also studied for eligibility and possible inclusion. Any 
iscrepancies between the two reviewers were discussed with a 
hird reviewer (NG) until a consensus had been achieved. 
In total, 33 published clinical studies were included in the cur- 
ent review for quantitative analyses. The first electronic online 
atabase search revealed 231 articles for evaluation, of which 98 
ull-text articles were retrieved for further adjudication and full- 
ext review after the removal of duplicates and reviews and af- 
er title and abstract screening. Two more articles were retrieved 
rom the reference list of relevant articles, which were then in- 
luded in the final review as well. We considered reasons for ex- 
lusion of quantitative analysis the following: home care-only pop- 
lation ( n = 1), ambulatory-only population ( n = 1), pregnancy 
nly ( n = 1) and healthcare providers ( n = 1), reaching a total of
3 studies for final analyses. Different phases of the information 
ow of the review are presented in Figure 1 . 
utcome, subgroup analysis, and statistical 
Our only outcome of interest was hospital mortality. We con- 
ucted 2 subgroup analyses restricted to studies with same char- 
cteristics population and a low risk of bias: (1) critical illness sub- 
roup analysis (7 studies); (2) general patients admitted to hospital 
ubgroup analysis (21 studies). 
The bias level was estimated using the Cochrane Collaboration 
isk-of-bias instrument [13] . 
Single-arm meta-analysis were performed using the statistical 
oftware package “meta” in R (version 3.3.3) and for a 5% sig- 
ificance level. Random-effect models were estimated using in- 
erse variance method. Logit transformation was performed on the 15 ata and continuity correction of 0.5 was applied in studies were 
ero frequencies were observed. Heterogeneity among studies was 
ested using τ 2 statistics and I 2 statistics. Funnel plot was used to 
etect the publication bias (Supplementary Figure 1). Models were 
stimated considering all studies, and according with general pa- 
ients admitted to hospital, critical illness, and severe population 
to characterize the population classified as general patients). 
esults 
tudy characteristics 
Most studies have limitations regarding quality and design with 
ubstantial qualitative heterogeneity among them. The 33 included 
tudies analyzed 13,398 patients, 60% were male. Three studies 
ave not specified the age of the participants and just for five 
tudies the mean age of the participants was below 50 years old. 
he age of participants varied between less than one year and 107 
ears. 
The majority of the included studies were from China (82%), 
epresenting 45% of all patients; other studies originated in the 
SA ( n = 3), Thailand ( n = 1), Italy ( n = 1) and Spain ( n = 1).
ixty four percent ( n = 21) of the studies report data on general
atients admitted to hospital, 21% ( n = 7) on critical illness cases, 
nd there were single studies on cancer, cardiothoracic, cardiovas- 
ular disease, elderly and pediatric patients. Comorbidities were 
escribed in 82% of the studies ( n = 27), diabetes in 96% of this
 n = 26, range 6% −58%), CVD in 78% ( n = 21, range 2.3% −53.7%),
TN in 78% ( n = 21, range 9.5% −56.6%), and COPD in 67% ( n = 18,
ange 1.4% −38.5%). The median follow-up duration of the studies 
as 29 days, with a minimum value of 9 and a maximum of 52 
ays. 
The rate of sever patients in studies described as general popu- 
ation was 20.4% (95% CI 13.7; 29.3, I 2 = 97.7%). 
The characteristics, demographic and clinical data of the in- 
luded studies are shown in Tables 1 and 2 . 
tudy quality appraisal and bias assessment 
Mortality rates were highly variable in the included studies 
range, 0% −62%), with zero mortality rates reported in the stud- 
es with lower follow-up. The study distribution was asymmetrical 
n both sides of the mean, mainly due to zero mortality studies, 
aising concerns for publication bias. 
uantitative synthesis of the study findings 
lobal mortality 
A total of 33 studies were included [14–46] with 13,398 pa- 
ients. The results of the random effects model meta-analysis 
howed that the mortality rate of the COVID-19 patients was 17.1% 
95%CI 12.7; 22.7, I 2 = 96.9%; Fig. 2 ). No significant heterogeneity 
as found using Cochran X 2 test for homogeneity at alpha = 0.10. 
ortality in general patients admitted to hospital (excluding critical 
are-only studies) 
A total of 21 studies included general patients admitted to hos- 
ital with 10,769 cases. The results of the random effects model 
eta-analysis showed that the mortality rate of the COVID-19 gen- 
ral patients was 11.5% (95%CI 7.7; 16.9, I 2 = 96.7%; Fig. 3 ). 
ortality in critical illness patients 
Seven studies were included for the analyses of critical illness 
ases, representing 2379 patients. The results of the random effects 
odel meta-analysis showed that the mortality rate of the COVID- 
9 critical illness patients was 40.5% (95% CI 31.2; 50.6, I 2 = 91.8%; 
ig. 4 ). 
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Table 1 
Characteristics of studies entered into meta-analysis 
Author Month Country City Local source Patient Group Total N N non survivors N severe 
Peng YD Mar, 2020 China Wuhan Hospital Cardiovascular disease 112 17 16 
Xiao Tang Mar, 2020 China Wuhan Hospital Critical illness 73 21 73 
Guan W-jie Mar, 2020 China National Hospital General 1590 50 254 
Tao Chen Mar, 2020 China Wuhan Hospital Critical illness 274 113 274 
Zhongliang Wang Mar, 2020 China Wuhan Hospital General 69 5 14 
Wang D Feb, 2020 China Wuhan Hospital General 138 6 36 
Yan Deng Mar, 2020 China Wuhan Hospital General 225 109 95 
Kui Liu Jan, 2020 China Wuhan Hospital General 137 16 –
Tao Guo Mar, 2020 China Wuhan Hospital General 187 43 –
Shaobo Shi Mar, 2020 China Wuhan Hospital General 416 57 –
Mingli Yuan Mar, 2020 China Wuhan Hospital General 27 10 –
Ning Tang Feb, 2020 China Wuhan Hospital General 183 21 –
Ning Tang Mar, 2020 China Wuhan Hospital General 449 134 97 
Yang-kai LI Mar, 2020 China Wuhan Hospital Cardiothoracic patients 13 5 7 
B. Cao Mar, 2020 China Wuhan Hospital General 199 44 32 
Pavan K. Bhatraju Mar, 2020 USA Seattle Hospital Critical illness 24 12 24 
Kai Liu Mar, 2020 China Hainan Hospital Elderly 56 3 6 
Fei Zhou Mar, 2020 China Wuhan Hospital General 191 54 66 
Sijia Tian Feb, 2020 China Beijing Hospital General 262 3 46 
L. Zhang Mar, 2020 China Wuhan Hospital Cancer patients 28 8 6 
Xiaobo Yang Feb, 2020 China Wuhan Hospital Critical illness 52 32 52 
Chaomin Wu Mar, 2020 China Wuhan Hospital General 201 44 84 
Yu Shi Mar, 2020 China Zhejiang Hospital General 487 0 49 
Lo Il Mar, 2020 China Macau Hospital General 10 0 4 
Matt Arentz Mar, 2020 USA Washington Hospital Critical illness 21 11 21 
Grasselli G Apr, 2020 Italy Lombardy Hospital Critical illness 1591 405 1591 
Zhou Y Mar, 2020 China Nanchang Hospital General 17 0 5 
Du RH Apr, 2020 China Wuhan Hospital General 179 21 –
Wang Y Apr, 2020 China Wuhan Hospital Critical illness 344 133 344 
Tagarro A Apr, 2020 Spain Madrid Hospital Pediatric 41 0 4 
Pongpirul WA Apr, 2020 Thailand Bangkok Hospital General 11 0 0 
Qian G-Q Mar, 2020 China Zhejiang Hospital General 91 0 9 
Richardson S Apr, 2020 USA New York Hospital General 5700 553 373 
Table 2 









Maximum Minimum HTN Diabetes CVD COPD 
Peng YD Mar, 2020 112 – – – – Non specified 
Xiao Tang Mar, 2020 73 67 72 57 45 51.2% 27.4% 31.5% 1.4% 
Guan W-jie Mar, 2020 1590 48.9 ± 16.3 – – 904 16.9% 8.2% 53.7% 1.5% 
Tao Chen Mar, 2020 274 62 70 44 171 34.0% 17.0% 8.0% 7.0% 
Zhongliang Wang Mar, 2020 69 42 62 35 32 13.0% 10.0% 12.0% 6.0% 
Wang D Feb, 2020 138 56 92 22 75 31.2% 10.1% 14.5% 2.9% 
Yan Deng Mar, 2020 225 69 74 62 73 36.7% 15.6% 11.9% 20.2% 
Kui Liu Jan, 2020 137 57 83 20 61 9.5% 10.2% 7.3% 1.5% 
Tao Guo Mar, 2020 187 58.5 ± 14.7 – – 91 32.6% 15.0% 11.2% 2.1% 
Shaobo Shi Mar, 2020 416 64 95 21 205 30.5% 14.4% – 2.9% 
Mingli Yuan Mar, 2020 27 60 69 47 12 19.0% 22.0% 11.0% –
Ning Tang Feb, 2020 183 54 94 14 98 non specified 
Ning Tang Mar, 2020 449 65.1 ± 12.0 – – 268 39.4% 20.7% 9.1% –
Yang-kai LI Mar, 2020 13 60.2 ± 5.6 – – 10 15.4% 7.7% 30.8% 38.5% 
B. Cao Mar, 2020 199 58 68 49 120 – 11.6% – –
Pavan K. Bhatraju Mar, 2020 24 64 97 23 15 – 58.0% – 4.0% 
Kai Liu Mar, 2020 56 – – – 12 27.8% 16.7% 11.1% –
Fei Zhou Mar, 2020 191 56 67 46 119 30.0% 19.0% 8.0% 3.0% 
Sijia Tian Feb, 2020 262 47.5 94 1 127 Non specified 
L. Zhang Mar, 2020 28 65 70 56 17 Non specified 
Xiaobo Yang Feb, 2020 52 59.7 – – 35 – 17.0% 10.0% 8.0% 
Chaomin Wu Mar, 2020 201 51 60 43 128 19.4% 10.9% 4.0% 2.5% 
Yu Shi Mar, 2020 487 46 – – 259 20.3% 6.0% 2.3% –
Lo Il Mar, 2020 10 54 64 27 3 30.0% 30.0% – –
Matt Arentz Mar, 2020 21 70 92 43 11 – 33.3% 42.9% 33.3% 
Grasselli G Apr, 2020 1591 63 70 56 1304 – 17.0% 21.0% 4.0% 
Zhou Y Mar, 2020 17 – 70 18 6 Non specified 
Du RH Apr, 2020 179 57.6 ± 13.7 87 18 97 32.4% 18.4% 16.2% –
Wang Y Apr, 2020 344 64 72 52 179 41.0% 18.6% 11.6% 4.7% 
Tagarro A Apr, 2020 41 3 6 0,9 18 Non specified 
Pongpirul WA Apr, 2020 11 61 74 28 6 36.0% 18.0% 27.0% 0.0% 
Qian G-Q Mar, 2020 91 50 96 5 37 16.5% 8.8% 3.3% –
Richardson S Apr, 2020 5700 63 107 0 3437 56.6% 33.8% – 5.4% 
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Our systematic review shows an overall 17% mortality rate for 
OVID-19 patients admitted to hospitals. General reports on death 
ates for the national populations in the different continents have 
hown different numbers. At present, the global mortality is 6.73%, 
hus much lower than the calculated from published studies, and 
t derives from the available information on confirmed cases and 
onfirmed deaths attributable to COVID-19, worldwide [47] (site 
ohns Hopkins, accessed on April 17, 2020). This shall be mainly 
xplained by the fact that patients included were predominately 
ospital admitted patients, being, supposedly, the more severe sub- 
roup of COVID-19 cases. 
In our subgroup analyses for patients admitted to hospitals, 
xcluding the studies that reported intensive care-only cases, the 
ortality rate decreased to 11.5%, reflecting a mixed population 
ffect. This case-mix of all COVID-19 hospital admitted cases in- 
luded approximately 20% of severe patients who needed highly 
omplex medical assistance and all patients who were admitted 
or social and public health reasons, irrespective of their clinical 
everity. 
In critical ill COVID-19 patients we report a 40.5% fatality rate, 
imilar to global ARDS outcomes [48] . The respiratory failure has 
een referred as the main cause for critical care admission of 
OVID-19 patients and ventilatory assistance is becoming the most 
llustrative treatment modality for severe manifestations of this 
cute infection. Although evidence is still growing on the best 
trategies for mechanical ventilation modes and other vital organ 
upport options, it is evident that high mortality is a characteristic 17 f severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
n our opinion, future research effort s shall be made on gathering 
orldwide detailed data to contribute to the development of the 
ost effective treatment modalities. 
The wider and heterogeneous criteria for the severity classifica- 
ion impose caution in the interpretation of this rate and impact 
he potential operational measures to address sicker patients ad- 
itted to hospitals. 
The high incidence of COVID-19 cases during this pandemic 
ustifies current effort s to increase the knowledge on the disease 
mong healthcare professionals and the general public. However, 
aution should be employed when interpreting our pooled esti- 
ates, given the high heterogeneity observed between studies. 
his variability in estimates could be driven by patient populations’ 
ountry of origin, as the Chinese-, European- and North American- 
pecific estimates suggest. The different methods of identifying 
ases, using discharge codes, administrative data, or electronic 
hart reviews, might also account for some of the differences. For 
xample, some case definition methods may underestimate the di- 
gnosis and significant numbers of patients may be misclassified. 
he differences observed might also be due to the timing varia- 
ions in the epidemiology curves of COVID-19 as the time period 
f the studies varied widely from a single week to several months. 
As length of follow-up is associated with different rates of 
eathly cases, in the way that studies with longer follow-up in- 
ospital periods tend to report higher rates, we must consider 
hese fatality rates provisional. According to the WHO, recovery 
ime from COVID-19 appears to be around two weeks for mild 
nfections and three to six weeks for severe disease [49] . By se- 
A. Macedo, N. Gonçalves and C. Febra Annals of Epidemiology 57 (2021) 14–21 
Fig. 2. Global mortality ratio. 
Fig. 3. Mortality in general patients admitted to hospital. 
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ecting studies on hospital series, we are including a proportion- 
lly higher fraction of severely diseased, and, consequently, with 
onger recovery times. The focused and tenacious effort s of the 
cientific community, from every corner of the world, in readily 
ublishing relevant data on COVID-19 patients, is markedly reduc- 
ng the duration of follow-up, comparing with usual epidemio- 
ogic studies. In these conditions, we shall assume that definite 
ate deaths counting will probably rise global fatality rates, beyond 
he 17% we report here. The unknown long-term consequences of 
his emergent disease may well significantly impact on mortal- 
ty rates, depending on the pathophysiology of its sequelae and, 
ventually aggravate the already high total economic cost of the 
isease. 
As studies are predominantly originating in China, and the 
vailable data on COVID-19 clinical characteristics and all outcomes 
ata coming from other countries concern intensive care patients, 
e specifically compared critical care populations between Chi- 
ese and non-Chinese coming from Washington, United States, and 
ombardy, Italy. These analyses revealed that an up-to-date under- 
tanding of the COVID-19 associated mortality is important to help 
uiding resource allocation for countries with a yet to rise number 
f new cases and, more importantly, for the expected forthcom- 
ng phase of repeated outbreaks. Additionally, these information on 
ortality are critical to inform healthcare budgets, as the economic 
mpact of this pandemic, although still incompletely evaluated, is 
lready known to be have a major impact on healthcare systems 
ll over the world. 
The results of our review should be interpreted with consid- 
ration of certain limitations. Firstly, we only included studies 
earched and indexed on occidental databases, potentially leading 
o language bias as relevant studies published in other languages, 
uch as Chinese or South Korean, were not included. Secondly, the 
road range of included studies resulted in a large amount of het- 
rogeneity that could not be fully explained by the variables we as- 
essed. Third, we were unable to specifically examine excess mor- 
ality due to co-morbidities, a matter of debate and that justifies 
urther research. Fourth, when looking into the mortality of any 
cute infectious disease which clinical course may vary from an 
symptomatic form to a rapidly fatal outcome, it is of the utter- 
ost importance to classify patients according to the severity of 
he disease. Unfortunately, we did not have access to gravity scores 
n most series of patients, nor to the variables necessary to calcu- 
ate or infer them, thus resulting in a clinical severity heterogene- 
ty that deserves detailed investigation on the upcoming weeks. 
In a sense, we believe this study will help to grow the exist- 
ng basis on the knowledge of a very recent disease and contribute 
o a better understanding of the dimension of its potentially fatal 
onsequences. Without minimizing the cautious critical judgment 
n generalizations of epidemiologic studies, the overall fatality of 
OVID-19 on hospital admitted patients should be taken into con- 
ideration in the care of these patients and be one more catalyzer a
19 f the ongoing investigation on new treatments and vaccine devel- 
pment. 
onclusion 
This analysis reports a higher mortality rate for both mixed- 
mbulatory and in-hospital patients and in-hospital-only cases. Al- 
hough we are still missing most of the data on COVID-19 patients, 
o be published in the near future, these rates shall help to guide 
esources allocations and economic burden calculations during the 
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